Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Psyence Biomedical Ltd (PBM)

Psyence Biomedical Ltd (PBM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs GlobeNewswire - Wed Nov 12, 6:00AM CST

NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Psyence BioMed (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies...

PBM : 2.71 (-2.87%)
Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care GlobeNewswire - Thu Nov 6, 6:00AM CST

NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...

PBM : 2.71 (-2.87%)
Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment GlobeNewswire - Mon Nov 3, 6:00AM CST

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and Ibogaine...

PBM : 2.71 (-2.87%)
Psyence Biomedical Announces Leadership Transition and Strategic Focus Tipranks - Fri Oct 10, 4:01PM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update...

PBM : 2.71 (-2.87%)
Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025 GlobeNewswire - Thu Aug 28, 7:00AM CDT

NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...

PBM : 2.71 (-2.87%)
Corporate Update, August 2025 GlobeNewswire - Mon Aug 4, 7:30AM CDT

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- From Dr. Neil Maresky, CEO, Psyence BioMed (NASDAQ: PBM) Dear Shareholders, Thank you for your continued support as we advance our mission to develop...

PBM : 2.71 (-2.87%)
Psyence BioMed’s Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production GlobeNewswire - Thu Jul 31, 6:30AM CDT

NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) is pleased to announce that its strategic partner, PsyLabs – a leader...

PBM : 2.71 (-2.87%)
Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025 Newsfile - Wed Jun 18, 7:38AM CDT

Investors, Entrepreneurs, and Industry Experts to Convene at the Premier Psychedelic Science Business Forum hosted by Multidisciplinary Association for Psychedelic Studies (MAPS)Denver, Colorado--(Newsfile...

PBM : 2.71 (-2.87%)
Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements Newsfile - Tue Jun 17, 7:06AM CDT

New York, New York--(Newsfile Corp. - June 17, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced that it has received formal notification from the Nasdaq...

PBM : 2.71 (-2.87%)
Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial Newsfile - Tue May 27, 6:30AM CDT

New York, New York--(Newsfile Corp. - May 27, 2025) - Psyence BioMed (NASDAQ: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company developing nature-derived psilocybin therapies for unmet...

PBM : 2.71 (-2.87%)

Barchart Exclusives

The Market Just Pulled Back. Here Is How To Protect Gains And Reset Risk Barchart - Sun Nov 16, 12:45PM CST
Investors panic during pullbacks because they react to emotion instead of structure. This piece shows how to protect gains, reset risk, and turn volatility into opportunity. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot